bluebird bio

bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer. Read more

Nick Leschly's photo - President & CEO of bluebird bio

President & CEO

Nick Leschly

CEO Approval Rating

73/100

Founded:

1992

Status:

PublicIndependent CompanyNASDAQBLUE

BLUEBIRD BIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Sangamo is the biggest rival of bluebird bio. Sangamo was founded in 1995, and its headquarters is in Brisbane, California. Sangamo operates in the Biotechnology industry. Sangamo has 351 fewer employees than bluebird bio.

Ember Therapeutics has been one of bluebird bio's top competitors. Ember Therapeutics is a Public company that was founded in New York, New York in 2011. Ember Therapeutics competes in the Health Care Services industry. Ember Therapeutics has 761 fewer employees vs. bluebird bio.

Recombinetics is bluebird bio's #3 rival. Recombinetics was founded in 2008 in Saint Paul, Minnesota. Recombinetics is in the Biotechnology industry. Recombinetics generates $234.5M less revenue than bluebird bio.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Immunocore a competitor of bluebird bio?

bluebird bio Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$241.7M

bluebird bio's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 499.5M. Over the last four quarters, bluebird bio's revenue has decreased by 93.6%. Specifically, in Q1 2021's revenue was $12.8M; in Q4 2020, it was $10.7M; in Q3 2020, it was $19.3M; in Q2 2020, bluebird bio's revenue was $198.9M.

bluebird bio Acquisitions

No recent acquisitions found related to bluebird bio

bluebird bio Funding History

Since bluebird bio was founded in 1992, it has participated in 8 rounds of funding. In total bluebird bio has raised $526.4M. bluebird bio's last funding round was on Dec 2016 for a total of $250.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Post-IPO Equity
Dec 2016
$250M
-
IPO
Jun 2013
$116.1M
-
Grant
Oct 2012
$9.3M
Series D
Jul 2012
$60M
Series C
Apr 2011
$30M

Since bluebird bio was founded in 1992, it has participated in 8 rounds of funding. In total bluebird bio has raised $526.4M. bluebird bio's last funding round was on Dec 2016 for a total of $250.0M

bluebird bio Investments

No recent investments found related to bluebird bio

bluebird bio News

June 10, 2021WRAL TechWire

FDA gives OK to Bluebird bio to resume gene therapy trials

Bluebird bio, a gene therapy company with manufacturing facilities in Durham, is resuming clinical tr... See more »
June 2, 2021BioSpace

bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2021

bluebird bio, Inc. announced that the Compensation Committee of the Company's Board of Directors appr... See more »
May 21, 2021The Business Journals: Philadelphia

Spark Therapeutics sues gene therapy rival Bluebird Bio

The Philadelphia gene therapy company is in court over a Boston-area gene therapy firm's marketing ca... See more »

bluebird bio Press Releases

April 13, 2021NewsFile

Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021

New York, New York--(Newsfile Corp. - April 13, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies i... See more »
April 13, 2021NewsFile

The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - April 13, 2021) - The Schall Law Firm, a national sharehol... See more »
April 13, 2021NewsFile

Rosen, National Trial Counsel, Encourages bluebird bio, Inc. Investors with Losses to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE

New York, New York--(Newsfile Corp. - April 13, 2021) - WHY: Rosen Law Firm, a global investor rights... See more »
April 11, 2021PR-Inside

Bronstein, Gewirtz & Grossman, LLC Reminds bluebird ...

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / April 11, 2021 / Bronstein, Gewirtz & Grossman, LLC notif... See more »
April 9, 2021PR-Inside

The Schall Law Firm Announces the Filing of a ...

(PR-inside.com) LOS ANGELES, CA / ACCESSWIRE / April 9, 2021 / The Schall Law Firm, a national shareh... See more »
April 7, 2021StreetInsider

Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc

NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor righ... See more »
April 6, 2021PR-Inside

Levi & Korsinsky, LLP ...

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Levi & Korsinsky, LLP announces that clas... See more »

bluebird bio Videos

September 18, 2019bluebird bio Youtube Channel

"The Vutrano Family" on YOUTUBE

August 7, 2019bluebird bio Youtube Channel

"bluebirds rise up" on YOUTUBE

July 31, 2019bluebird bio Youtube Channel

"Deb & Allan: bluebird day" on YOUTUBE

July 8, 2019bluebird bio Youtube Channel

"How bluebird bio got it's name" on YOUTUBE

November 30, 2018bluebird Youtube Channel

"Why I Fly Kristin Wolff" on YOUTUBE

November 2, 2018bluebird bio Youtube Channel

"Why I Fly - Mark Omobono" on YOUTUBE

Social Media

bluebird bio Headquarters

60 Binney Street

Cambridge, Massachusetts02142

339-499-9300

Driving Directions »

Trending Companies

bluebird bio Summary

ABOUT

Overview

bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer. bluebird bio was founded in 1992. bluebird bio's headquarters is located in Cambridge, Massachusetts, USA 02142. It has raised 526.4M in 8 rounds. The...

CEO

bluebird bio's President & CEO, Nick Leschly, currently has an approval rating of 73%. bluebird bio's primary competitors are Sangamo, Ember Therapeutics & Recombinetics.

Frequently Asked Questions about bluebird bio

  1. When was bluebird bio founded?

    bluebird bio was founded in 1992
  2. Who is bluebird bio's CEO?

    bluebird bio's CEO is Nick Leschly
  3. How much revenue does bluebird bio generate?

    bluebird bio generates $241.7M in revenue
  4. How much funding does bluebird bio have?

    bluebird bio has historically raised $526.4M in funding
  1. Where is bluebird bio's headquarters?

    bluebird bio's headquarters is in Cambridge Massachusetts, USA
  2. How many employees does bluebird bio have?

    bluebird bio has 764 employees
  3. What sector does bluebird bio operate in?

    bluebird bio is in Biotechnology, Pharmaceuticals
  4. Who are bluebird bio's competitors?

    bluebird bio's top competitors are Sangamo, Ember Therapeutics, Recombinetics